EMA’s safety committee recommends suspending preterm birth drugs

The Eu­ro­pean Med­i­cines Agency is tak­ing aim at preterm birth drugs, with the agency’s safe­ty com­mit­tee rec­om­mend­ing that med­i­cines con­tain­ing 17-hy­drox­yprog­es­terone caproate, al­so known as 17-OH­PC, be sus­pend­ed.

A re­view by the safe­ty com­mit­tee “con­clud­ed that there is a pos­si­ble but un­con­firmed risk of can­cer in peo­ple ex­posed to 17-OH­PC in the womb,” as well as ques­tions around its ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Could This Neuroleptic Ward Off RA?

Patients taking haloperidol were significantly less likely to develop new-onset rheumatoid arthritis (RA), relative to those receiving other antipsychotic medications, researchers found. Data pooled from

Read More »
September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Subscribe

* indicates required